DE69408962T2 - Naphthalen-Derivate mit Affinität für Melatonin-Rezeptoren, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen - Google Patents
Naphthalen-Derivate mit Affinität für Melatonin-Rezeptoren, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische ZusammensetzungenInfo
- Publication number
- DE69408962T2 DE69408962T2 DE69408962T DE69408962T DE69408962T2 DE 69408962 T2 DE69408962 T2 DE 69408962T2 DE 69408962 T DE69408962 T DE 69408962T DE 69408962 T DE69408962 T DE 69408962T DE 69408962 T2 DE69408962 T2 DE 69408962T2
- Authority
- DE
- Germany
- Prior art keywords
- ethyl
- alkyl
- naphth
- substituted
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims description 31
- 230000008569 process Effects 0.000 title claims description 4
- 238000002360 preparation method Methods 0.000 title claims description 3
- 150000002790 naphthalenes Chemical class 0.000 title abstract description 5
- 102000001419 Melatonin receptor Human genes 0.000 title description 7
- 108050009605 Melatonin receptor Proteins 0.000 title description 7
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 46
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 22
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims abstract description 19
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 10
- 125000001624 naphthyl group Chemical group 0.000 claims abstract description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 10
- 239000002253 acid Substances 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 9
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 8
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 7
- 150000002367 halogens Chemical class 0.000 claims abstract description 7
- 125000001424 substituent group Chemical group 0.000 claims abstract description 4
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims abstract description 3
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims abstract description 3
- 125000002541 furyl group Chemical group 0.000 claims abstract description 3
- 125000001041 indolyl group Chemical group 0.000 claims abstract description 3
- 125000005956 isoquinolyl group Chemical group 0.000 claims abstract description 3
- 125000004076 pyridyl group Chemical group 0.000 claims abstract description 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims abstract description 3
- 125000005493 quinolyl group Chemical group 0.000 claims abstract description 3
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 3
- 125000001544 thienyl group Chemical group 0.000 claims abstract description 3
- 150000001875 compounds Chemical class 0.000 claims description 112
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 24
- 238000011282 treatment Methods 0.000 claims description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 125000003884 phenylalkyl group Chemical group 0.000 claims description 6
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 6
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 6
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 5
- 230000001193 melatoninergic effect Effects 0.000 claims description 5
- 208000019116 sleep disease Diseases 0.000 claims description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- 238000002425 crystallisation Methods 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- RINDSMFIKZENOD-UHFFFAOYSA-N n-[2-(3-acetyl-7-methoxynaphthalen-1-yl)ethyl]acetamide Chemical compound C1=C(C(C)=O)C=C(CCNC(C)=O)C2=CC(OC)=CC=C21 RINDSMFIKZENOD-UHFFFAOYSA-N 0.000 claims description 4
- ZLLSNBDNTLZOKV-UHFFFAOYSA-N n-[2-(3-ethyl-7-methoxynaphthalen-1-yl)ethyl]acetamide Chemical compound C1=C(OC)C=CC2=CC(CC)=CC(CCNC(C)=O)=C21 ZLLSNBDNTLZOKV-UHFFFAOYSA-N 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 208000012672 seasonal affective disease Diseases 0.000 claims description 4
- 125000006528 (C2-C6) alkyl group Chemical group 0.000 claims description 3
- 238000006220 Baeyer-Villiger oxidation reaction Methods 0.000 claims description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 206010022437 insomnia Diseases 0.000 claims description 3
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 claims description 3
- 229910052753 mercury Inorganic materials 0.000 claims description 3
- XIEFMYDVCYTPLW-UHFFFAOYSA-N n-[2-(3-benzoyl-7-methoxynaphthalen-1-yl)ethyl]acetamide Chemical compound C1=C(CCNC(C)=O)C2=CC(OC)=CC=C2C=C1C(=O)C1=CC=CC=C1 XIEFMYDVCYTPLW-UHFFFAOYSA-N 0.000 claims description 3
- CHYQKKNIFZYCQW-UHFFFAOYSA-N n-[2-(4-acetylnaphthalen-1-yl)ethyl]acetamide Chemical compound C1=CC=C2C(CCNC(=O)C)=CC=C(C(C)=O)C2=C1 CHYQKKNIFZYCQW-UHFFFAOYSA-N 0.000 claims description 3
- 230000003647 oxidation Effects 0.000 claims description 3
- 238000007254 oxidation reaction Methods 0.000 claims description 3
- 230000001575 pathological effect Effects 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 230000009467 reduction Effects 0.000 claims description 3
- 239000011347 resin Substances 0.000 claims description 3
- 229920005989 resin Polymers 0.000 claims description 3
- 238000007127 saponification reaction Methods 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 208000027559 Appetite disease Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- NGLDTEKCMSJMSH-UHFFFAOYSA-N n-[2-(3-acetyl-7-methoxynaphthalen-1-yl)ethyl]cyclopropanecarboxamide Chemical compound C12=CC(OC)=CC=C2C=C(C(C)=O)C=C1CCNC(=O)C1CC1 NGLDTEKCMSJMSH-UHFFFAOYSA-N 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 2
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 2
- 125000004434 sulfur atom Chemical group 0.000 claims description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 abstract description 4
- 229910052760 oxygen Inorganic materials 0.000 abstract description 2
- 230000003287 optical effect Effects 0.000 abstract 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 150000001408 amides Chemical class 0.000 description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 13
- 230000033764 rhythmic process Effects 0.000 description 13
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 229910052739 hydrogen Inorganic materials 0.000 description 12
- 238000002844 melting Methods 0.000 description 12
- 230000008018 melting Effects 0.000 description 12
- 239000002904 solvent Substances 0.000 description 11
- 238000004452 microanalysis Methods 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 9
- 229960003987 melatonin Drugs 0.000 description 9
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 9
- 238000001953 recrystallisation Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 8
- 238000002329 infrared spectrum Methods 0.000 description 8
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 230000000302 ischemic effect Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 241001494479 Pecora Species 0.000 description 4
- 230000000202 analgesic effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 235000011167 hydrochloric acid Nutrition 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 208000024827 Alzheimer disease Diseases 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000006742 locomotor activity Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000004089 microcirculation Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 230000000561 anti-psychotic effect Effects 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 210000002565 arteriole Anatomy 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000010520 demethylation reaction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- CYEBJEDOHLIWNP-UHFFFAOYSA-N methanethioamide Chemical class NC=S CYEBJEDOHLIWNP-UHFFFAOYSA-N 0.000 description 2
- -1 methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, pentyloxy Chemical group 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- SESJHMFEZOINAH-UHFFFAOYSA-N n-[2-(3-benzoylnaphthalen-1-yl)ethyl]acetamide Chemical compound C=1C2=CC=CC=C2C(CCNC(=O)C)=CC=1C(=O)C1=CC=CC=C1 SESJHMFEZOINAH-UHFFFAOYSA-N 0.000 description 2
- WMHXHIDJVRTFDK-UHFFFAOYSA-N n-[2-(7-methoxy-3-propanoylnaphthalen-1-yl)ethyl]acetamide Chemical compound C1=C(OC)C=CC2=CC(C(=O)CC)=CC(CCNC(C)=O)=C21 WMHXHIDJVRTFDK-UHFFFAOYSA-N 0.000 description 2
- AGJNRNIEUYRJMA-UHFFFAOYSA-N n-[2-[3-(cyclopropanecarbonyl)-7-methoxynaphthalen-1-yl]ethyl]acetamide Chemical compound C1=C(CCNC(C)=O)C2=CC(OC)=CC=C2C=C1C(=O)C1CC1 AGJNRNIEUYRJMA-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- NPFMGXWHUSCPFQ-UHFFFAOYSA-N 1-[2-(3-acetyl-7-methoxynaphthalen-1-yl)ethyl]-3-cyclohexylurea Chemical compound C12=CC(OC)=CC=C2C=C(C(C)=O)C=C1CCNC(=O)NC1CCCCC1 NPFMGXWHUSCPFQ-UHFFFAOYSA-N 0.000 description 1
- ZVJAAHVPMASBPF-UHFFFAOYSA-N 1-[2-(3-acetyl-7-methoxynaphthalen-1-yl)ethyl]-3-cyclopropylurea Chemical compound C12=CC(OC)=CC=C2C=C(C(C)=O)C=C1CCNC(=O)NC1CC1 ZVJAAHVPMASBPF-UHFFFAOYSA-N 0.000 description 1
- PQGKCBCFDPHHPB-UHFFFAOYSA-N 1-[2-(3-acetyl-7-methoxynaphthalen-1-yl)ethyl]-3-ethylurea Chemical compound C1=C(OC)C=C2C(CCNC(=O)NCC)=CC(C(C)=O)=CC2=C1 PQGKCBCFDPHHPB-UHFFFAOYSA-N 0.000 description 1
- FTEOKNGNYREDIW-UHFFFAOYSA-N 1-[2-(3-acetyl-7-methoxynaphthalen-1-yl)ethyl]-3-hexylurea Chemical compound C1=C(OC)C=C2C(CCNC(=O)NCCCCCC)=CC(C(C)=O)=CC2=C1 FTEOKNGNYREDIW-UHFFFAOYSA-N 0.000 description 1
- GTXKZCCBBWIVBA-UHFFFAOYSA-N 1-[2-(3-acetyl-7-methoxynaphthalen-1-yl)ethyl]-3-methylurea Chemical compound C1=C(OC)C=C2C(CCNC(=O)NC)=CC(C(C)=O)=CC2=C1 GTXKZCCBBWIVBA-UHFFFAOYSA-N 0.000 description 1
- GSYLQQJYSNMGPQ-UHFFFAOYSA-N 1-[2-(3-acetyl-7-methoxynaphthalen-1-yl)ethyl]-3-propylurea Chemical compound C1=C(OC)C=C2C(CCNC(=O)NCCC)=CC(C(C)=O)=CC2=C1 GSYLQQJYSNMGPQ-UHFFFAOYSA-N 0.000 description 1
- PZQRCTYMHDXVOM-UHFFFAOYSA-N 1-[2-(3-benzoyl-7-methoxynaphthalen-1-yl)ethyl]-3-cyclohexylurea Chemical compound C12=CC(OC)=CC=C2C=C(C(=O)C=2C=CC=CC=2)C=C1CCNC(=O)NC1CCCCC1 PZQRCTYMHDXVOM-UHFFFAOYSA-N 0.000 description 1
- IIZLLKRPDJWAEX-UHFFFAOYSA-N 1-[2-(3-benzoyl-7-methoxynaphthalen-1-yl)ethyl]-3-cyclopropylurea Chemical compound C12=CC(OC)=CC=C2C=C(C(=O)C=2C=CC=CC=2)C=C1CCNC(=O)NC1CC1 IIZLLKRPDJWAEX-UHFFFAOYSA-N 0.000 description 1
- KXOVIVDIYOFVFC-UHFFFAOYSA-N 1-[2-(3-benzoyl-7-methoxynaphthalen-1-yl)ethyl]-3-ethylurea Chemical compound C=1C2=CC=C(OC)C=C2C(CCNC(=O)NCC)=CC=1C(=O)C1=CC=CC=C1 KXOVIVDIYOFVFC-UHFFFAOYSA-N 0.000 description 1
- HARCZXNFZKBARV-UHFFFAOYSA-N 1-[2-(3-benzoyl-7-methoxynaphthalen-1-yl)ethyl]-3-hexylurea Chemical compound C=1C2=CC=C(OC)C=C2C(CCNC(=O)NCCCCCC)=CC=1C(=O)C1=CC=CC=C1 HARCZXNFZKBARV-UHFFFAOYSA-N 0.000 description 1
- QMDFGDNNTNVGHI-UHFFFAOYSA-N 1-[2-(3-benzoyl-7-methoxynaphthalen-1-yl)ethyl]-3-methylurea Chemical compound C=1C2=CC=C(OC)C=C2C(CCNC(=O)NC)=CC=1C(=O)C1=CC=CC=C1 QMDFGDNNTNVGHI-UHFFFAOYSA-N 0.000 description 1
- FMPHJCIGSRCJDB-UHFFFAOYSA-N 1-[2-(3-benzoyl-7-methoxynaphthalen-1-yl)ethyl]-3-propylurea Chemical compound C=1C2=CC=C(OC)C=C2C(CCNC(=O)NCCC)=CC=1C(=O)C1=CC=CC=C1 FMPHJCIGSRCJDB-UHFFFAOYSA-N 0.000 description 1
- BKQDEOXXXRYJJM-UHFFFAOYSA-N 1-[2-(3-benzyl-7-methoxynaphthalen-1-yl)ethyl]-3-cyclohexylurea Chemical compound C1=C(CCNC(=O)NC2CCCCC2)C2=CC(OC)=CC=C2C=C1CC1=CC=CC=C1 BKQDEOXXXRYJJM-UHFFFAOYSA-N 0.000 description 1
- HMQGSPQEGNSSTN-UHFFFAOYSA-N 1-[2-(3-benzyl-7-methoxynaphthalen-1-yl)ethyl]-3-cyclopropylurea Chemical compound C1=C(CCNC(=O)NC2CC2)C2=CC(OC)=CC=C2C=C1CC1=CC=CC=C1 HMQGSPQEGNSSTN-UHFFFAOYSA-N 0.000 description 1
- KIHWSKNEMASMDB-UHFFFAOYSA-N 1-[2-(3-benzyl-7-methoxynaphthalen-1-yl)ethyl]-3-ethylurea Chemical compound C=1C2=CC=C(OC)C=C2C(CCNC(=O)NCC)=CC=1CC1=CC=CC=C1 KIHWSKNEMASMDB-UHFFFAOYSA-N 0.000 description 1
- ADHRSYOOKSRZFB-UHFFFAOYSA-N 1-[2-(3-benzyl-7-methoxynaphthalen-1-yl)ethyl]-3-hexylurea Chemical compound C=1C2=CC=C(OC)C=C2C(CCNC(=O)NCCCCCC)=CC=1CC1=CC=CC=C1 ADHRSYOOKSRZFB-UHFFFAOYSA-N 0.000 description 1
- ZDMYZDQBYAOQFN-UHFFFAOYSA-N 1-[2-(3-benzyl-7-methoxynaphthalen-1-yl)ethyl]-3-methylurea Chemical compound C=1C2=CC=C(OC)C=C2C(CCNC(=O)NC)=CC=1CC1=CC=CC=C1 ZDMYZDQBYAOQFN-UHFFFAOYSA-N 0.000 description 1
- SVGCXWWLTBXABK-UHFFFAOYSA-N 1-[2-(3-benzyl-7-methoxynaphthalen-1-yl)ethyl]-3-propylurea Chemical compound C=1C2=CC=C(OC)C=C2C(CCNC(=O)NCCC)=CC=1CC1=CC=CC=C1 SVGCXWWLTBXABK-UHFFFAOYSA-N 0.000 description 1
- VMBRLDJCPKPWFY-UHFFFAOYSA-N 1-[2-(3-ethyl-7-methoxynaphthalen-1-yl)ethyl]-3-hexylurea Chemical compound C1=C(OC)C=C2C(CCNC(=O)NCCCCCC)=CC(CC)=CC2=C1 VMBRLDJCPKPWFY-UHFFFAOYSA-N 0.000 description 1
- QSCNEEYLWUFKIN-UHFFFAOYSA-N 1-[2-(3-ethyl-7-methoxynaphthalen-1-yl)ethyl]-3-methylurea Chemical compound C1=C(OC)C=CC2=CC(CC)=CC(CCNC(=O)NC)=C21 QSCNEEYLWUFKIN-UHFFFAOYSA-N 0.000 description 1
- JBNLBQYIOXULMQ-UHFFFAOYSA-N 1-[2-(3-ethyl-7-methoxynaphthalen-1-yl)ethyl]-3-propylurea Chemical compound C1=C(OC)C=C2C(CCNC(=O)NCCC)=CC(CC)=CC2=C1 JBNLBQYIOXULMQ-UHFFFAOYSA-N 0.000 description 1
- MSCAJNROZWGNPZ-UHFFFAOYSA-N 1-[2-(7-methoxy-3-propanoylnaphthalen-1-yl)ethyl]-3-propylurea Chemical compound C1=C(OC)C=C2C(CCNC(=O)NCCC)=CC(C(=O)CC)=CC2=C1 MSCAJNROZWGNPZ-UHFFFAOYSA-N 0.000 description 1
- VEWXUWQUHBGYLN-UHFFFAOYSA-N 1-[2-[3-(cyclopropanecarbonyl)-7-methoxynaphthalen-1-yl]ethyl]-3-methylurea Chemical compound C=1C2=CC=C(OC)C=C2C(CCNC(=O)NC)=CC=1C(=O)C1CC1 VEWXUWQUHBGYLN-UHFFFAOYSA-N 0.000 description 1
- SLCYQQYOUDDSJC-UHFFFAOYSA-N 1-[2-[3-(cyclopropanecarbonyl)-7-methoxynaphthalen-1-yl]ethyl]-3-propylurea Chemical compound C=1C2=CC=C(OC)C=C2C(CCNC(=O)NCCC)=CC=1C(=O)C1CC1 SLCYQQYOUDDSJC-UHFFFAOYSA-N 0.000 description 1
- JRGPQUJPELAXOG-UHFFFAOYSA-N 1-cyclohexyl-3-[2-(3-ethyl-7-methoxynaphthalen-1-yl)ethyl]urea Chemical compound C=12C=C(OC)C=CC2=CC(CC)=CC=1CCNC(=O)NC1CCCCC1 JRGPQUJPELAXOG-UHFFFAOYSA-N 0.000 description 1
- QCUWDXCTWSXIOL-UHFFFAOYSA-N 1-cyclopropyl-3-[2-(3-ethyl-7-methoxynaphthalen-1-yl)ethyl]urea Chemical compound C=12C=C(OC)C=CC2=CC(CC)=CC=1CCNC(=O)NC1CC1 QCUWDXCTWSXIOL-UHFFFAOYSA-N 0.000 description 1
- FWWXWIQPCHGZGP-UHFFFAOYSA-N 1-ethyl-3-[2-(3-ethyl-7-methoxynaphthalen-1-yl)ethyl]urea Chemical compound C1=C(OC)C=C2C(CCNC(=O)NCC)=CC(CC)=CC2=C1 FWWXWIQPCHGZGP-UHFFFAOYSA-N 0.000 description 1
- GLVYLTSKTCWWJR-UHFFFAOYSA-N 2-carbonoperoxoylbenzoic acid Chemical compound OOC(=O)C1=CC=CC=C1C(O)=O GLVYLTSKTCWWJR-UHFFFAOYSA-N 0.000 description 1
- RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 229910000497 Amalgam Inorganic materials 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- LSPHULWDVZXLIL-UHFFFAOYSA-N Camphoric acid Natural products CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- YUMRMOPFVLXDPU-UHFFFAOYSA-N [4-(2-acetamidoethyl)-6-methoxynaphthalen-2-yl] acetate Chemical compound C1=C(OC(C)=O)C=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YUMRMOPFVLXDPU-UHFFFAOYSA-N 0.000 description 1
- FJRLCAQRLYUPMW-UHFFFAOYSA-N [4-[2-(cyclobutanecarbonylamino)ethyl]-6-methoxynaphthalen-2-yl] acetate Chemical compound C12=CC(OC)=CC=C2C=C(OC(C)=O)C=C1CCNC(=O)C1CCC1 FJRLCAQRLYUPMW-UHFFFAOYSA-N 0.000 description 1
- QZJWFAHOMYDAQJ-UHFFFAOYSA-N [4-[2-(cyclopropanecarbonylamino)ethyl]-6-methoxynaphthalen-2-yl] acetate Chemical compound C12=CC(OC)=CC=C2C=C(OC(C)=O)C=C1CCNC(=O)C1CC1 QZJWFAHOMYDAQJ-UHFFFAOYSA-N 0.000 description 1
- WDYQKXHFPKDNSQ-UHFFFAOYSA-N [6-methoxy-4-[2-(propanoylamino)ethyl]naphthalen-2-yl] acetate Chemical compound C1=C(OC)C=C2C(CCNC(=O)CC)=CC(OC(C)=O)=CC2=C1 WDYQKXHFPKDNSQ-UHFFFAOYSA-N 0.000 description 1
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical group [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 235000021407 appetite control Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000773 effect on pain Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 210000003090 iliac artery Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- CFHGBZLNZZVTAY-UHFFFAOYSA-N lawesson's reagent Chemical compound C1=CC(OC)=CC=C1P1(=S)SP(=S)(C=2C=CC(OC)=CC=2)S1 CFHGBZLNZZVTAY-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000013289 male long evans rat Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- FMUHSDLSKQLNNB-UHFFFAOYSA-N n-[2-(3,7-dihydroxynaphthalen-1-yl)ethyl]acetamide Chemical compound C1=C(O)C=C2C(CCNC(=O)C)=CC(O)=CC2=C1 FMUHSDLSKQLNNB-UHFFFAOYSA-N 0.000 description 1
- AKMPRLRELFXGKK-UHFFFAOYSA-N n-[2-(3,7-dihydroxynaphthalen-1-yl)ethyl]cyclobutanecarboxamide Chemical compound C12=CC(O)=CC=C2C=C(O)C=C1CCNC(=O)C1CCC1 AKMPRLRELFXGKK-UHFFFAOYSA-N 0.000 description 1
- YWBVAQCEBUMKGM-UHFFFAOYSA-N n-[2-(3,7-dihydroxynaphthalen-1-yl)ethyl]cyclopropanecarboxamide Chemical compound C12=CC(O)=CC=C2C=C(O)C=C1CCNC(=O)C1CC1 YWBVAQCEBUMKGM-UHFFFAOYSA-N 0.000 description 1
- VQUUQWKCUUALGP-UHFFFAOYSA-N n-[2-(3,7-dihydroxynaphthalen-1-yl)ethyl]propanamide Chemical compound C1=C(O)C=C2C(CCNC(=O)CC)=CC(O)=CC2=C1 VQUUQWKCUUALGP-UHFFFAOYSA-N 0.000 description 1
- GSJNHQDSDVOFCQ-UHFFFAOYSA-N n-[2-(3-acetyl-7-cyclohexyloxynaphthalen-1-yl)ethyl]acetamide Chemical compound C1=C2C(CCNC(=O)C)=CC(C(C)=O)=CC2=CC=C1OC1CCCCC1 GSJNHQDSDVOFCQ-UHFFFAOYSA-N 0.000 description 1
- XICDVXBZENLTQK-UHFFFAOYSA-N n-[2-(3-acetyl-7-ethoxynaphthalen-1-yl)ethyl]acetamide Chemical compound C1=C(C(C)=O)C=C(CCNC(C)=O)C2=CC(OCC)=CC=C21 XICDVXBZENLTQK-UHFFFAOYSA-N 0.000 description 1
- LFQVQTIXEXQIFW-UHFFFAOYSA-N n-[2-(3-acetyl-7-methoxynaphthalen-1-yl)ethyl]butanamide Chemical compound C1=C(OC)C=C2C(CCNC(=O)CCC)=CC(C(C)=O)=CC2=C1 LFQVQTIXEXQIFW-UHFFFAOYSA-N 0.000 description 1
- LDLIIVDJXUUYFT-UHFFFAOYSA-N n-[2-(3-acetyl-7-methoxynaphthalen-1-yl)ethyl]cyclobutanecarboxamide Chemical compound C12=CC(OC)=CC=C2C=C(C(C)=O)C=C1CCNC(=O)C1CCC1 LDLIIVDJXUUYFT-UHFFFAOYSA-N 0.000 description 1
- GEVYVXFXEHDONE-UHFFFAOYSA-N n-[2-(3-acetyl-7-methoxynaphthalen-1-yl)ethyl]cyclohexanecarboxamide Chemical compound C12=CC(OC)=CC=C2C=C(C(C)=O)C=C1CCNC(=O)C1CCCCC1 GEVYVXFXEHDONE-UHFFFAOYSA-N 0.000 description 1
- ASBZJZSIQKHCEO-UHFFFAOYSA-N n-[2-(3-acetyl-7-methoxynaphthalen-1-yl)ethyl]cyclopentanecarboxamide Chemical compound C12=CC(OC)=CC=C2C=C(C(C)=O)C=C1CCNC(=O)C1CCCC1 ASBZJZSIQKHCEO-UHFFFAOYSA-N 0.000 description 1
- FXYFUWBNDFSJRL-UHFFFAOYSA-N n-[2-(3-acetyl-7-methoxynaphthalen-1-yl)ethyl]cyclopropanecarbothioamide Chemical compound C12=CC(OC)=CC=C2C=C(C(C)=O)C=C1CCNC(=S)C1CC1 FXYFUWBNDFSJRL-UHFFFAOYSA-N 0.000 description 1
- FKRUAXNAPHZKPT-UHFFFAOYSA-N n-[2-(3-acetyl-7-methoxynaphthalen-1-yl)ethyl]ethanethioamide Chemical compound C1=C(C(C)=O)C=C(CCNC(C)=S)C2=CC(OC)=CC=C21 FKRUAXNAPHZKPT-UHFFFAOYSA-N 0.000 description 1
- XSFQTDZZIAZJJR-UHFFFAOYSA-N n-[2-(3-acetyl-7-methoxynaphthalen-1-yl)ethyl]hexanamide Chemical compound C1=C(OC)C=C2C(CCNC(=O)CCCCC)=CC(C(C)=O)=CC2=C1 XSFQTDZZIAZJJR-UHFFFAOYSA-N 0.000 description 1
- AFAGZFQYXYFDCP-UHFFFAOYSA-N n-[2-(3-acetyl-7-methoxynaphthalen-1-yl)ethyl]pentanamide Chemical compound C1=C(OC)C=C2C(CCNC(=O)CCCC)=CC(C(C)=O)=CC2=C1 AFAGZFQYXYFDCP-UHFFFAOYSA-N 0.000 description 1
- JDIDPRFYYDKXCF-UHFFFAOYSA-N n-[2-(3-acetyl-7-methoxynaphthalen-1-yl)ethyl]propanamide Chemical compound C1=C(OC)C=C2C(CCNC(=O)CC)=CC(C(C)=O)=CC2=C1 JDIDPRFYYDKXCF-UHFFFAOYSA-N 0.000 description 1
- WBPDGZXMAJPMAW-UHFFFAOYSA-N n-[2-(3-acetyl-7-pentoxynaphthalen-1-yl)ethyl]acetamide Chemical compound C1=C(C(C)=O)C=C(CCNC(C)=O)C2=CC(OCCCCC)=CC=C21 WBPDGZXMAJPMAW-UHFFFAOYSA-N 0.000 description 1
- DMICZMKDETVYPK-UHFFFAOYSA-N n-[2-(3-acetyl-7-phenylmethoxynaphthalen-1-yl)ethyl]acetamide Chemical compound C1=C2C(CCNC(=O)C)=CC(C(C)=O)=CC2=CC=C1OCC1=CC=CC=C1 DMICZMKDETVYPK-UHFFFAOYSA-N 0.000 description 1
- NURQZDWPVFPHQY-UHFFFAOYSA-N n-[2-(3-acetyl-7-prop-2-ynoxynaphthalen-1-yl)ethyl]acetamide Chemical compound C1=C(OCC#C)C=C2C(CCNC(=O)C)=CC(C(C)=O)=CC2=C1 NURQZDWPVFPHQY-UHFFFAOYSA-N 0.000 description 1
- IAMYJMLSLYPZJK-UHFFFAOYSA-N n-[2-(3-acetyl-7-propoxynaphthalen-1-yl)ethyl]acetamide Chemical compound C1=C(C(C)=O)C=C(CCNC(C)=O)C2=CC(OCCC)=CC=C21 IAMYJMLSLYPZJK-UHFFFAOYSA-N 0.000 description 1
- GJRPMGUMPHEPJO-UHFFFAOYSA-N n-[2-(3-acetylnaphthalen-1-yl)ethyl]acetamide Chemical compound C1=CC=C2C(CCNC(=O)C)=CC(C(C)=O)=CC2=C1 GJRPMGUMPHEPJO-UHFFFAOYSA-N 0.000 description 1
- DHKSHSOXZOCHOF-UHFFFAOYSA-N n-[2-(3-acetylnaphthalen-1-yl)ethyl]cyclobutanecarboxamide Chemical compound C=12C=CC=CC2=CC(C(=O)C)=CC=1CCNC(=O)C1CCC1 DHKSHSOXZOCHOF-UHFFFAOYSA-N 0.000 description 1
- JAWAUSJQJMQGSH-UHFFFAOYSA-N n-[2-(3-acetylnaphthalen-1-yl)ethyl]cyclopropanecarboxamide Chemical compound C=12C=CC=CC2=CC(C(=O)C)=CC=1CCNC(=O)C1CC1 JAWAUSJQJMQGSH-UHFFFAOYSA-N 0.000 description 1
- BPEIUQLHHKCYBA-UHFFFAOYSA-N n-[2-(3-benzoyl-7-cyclohexyloxynaphthalen-1-yl)ethyl]acetamide Chemical compound C1=C2C(CCNC(=O)C)=CC(C(=O)C=3C=CC=CC=3)=CC2=CC=C1OC1CCCCC1 BPEIUQLHHKCYBA-UHFFFAOYSA-N 0.000 description 1
- OLUBBYLOTLQKFR-UHFFFAOYSA-N n-[2-(3-benzoyl-7-ethoxynaphthalen-1-yl)ethyl]acetamide Chemical compound C1=C(CCNC(C)=O)C2=CC(OCC)=CC=C2C=C1C(=O)C1=CC=CC=C1 OLUBBYLOTLQKFR-UHFFFAOYSA-N 0.000 description 1
- INZNJUIYSCCJFU-UHFFFAOYSA-N n-[2-(3-benzoyl-7-methoxynaphthalen-1-yl)ethyl]butanamide Chemical compound C=1C2=CC=C(OC)C=C2C(CCNC(=O)CCC)=CC=1C(=O)C1=CC=CC=C1 INZNJUIYSCCJFU-UHFFFAOYSA-N 0.000 description 1
- PTPDWKDVPWBDAD-UHFFFAOYSA-N n-[2-(3-benzoyl-7-methoxynaphthalen-1-yl)ethyl]cyclobutanecarboxamide Chemical compound C12=CC(OC)=CC=C2C=C(C(=O)C=2C=CC=CC=2)C=C1CCNC(=O)C1CCC1 PTPDWKDVPWBDAD-UHFFFAOYSA-N 0.000 description 1
- FVURYQQPIJZOBR-UHFFFAOYSA-N n-[2-(3-benzoyl-7-methoxynaphthalen-1-yl)ethyl]cyclohexanecarboxamide Chemical compound C12=CC(OC)=CC=C2C=C(C(=O)C=2C=CC=CC=2)C=C1CCNC(=O)C1CCCCC1 FVURYQQPIJZOBR-UHFFFAOYSA-N 0.000 description 1
- MEYAYPCKCIYAEN-UHFFFAOYSA-N n-[2-(3-benzoyl-7-methoxynaphthalen-1-yl)ethyl]cyclopentanecarboxamide Chemical compound C12=CC(OC)=CC=C2C=C(C(=O)C=2C=CC=CC=2)C=C1CCNC(=O)C1CCCC1 MEYAYPCKCIYAEN-UHFFFAOYSA-N 0.000 description 1
- SUHJKACZNPFDHW-UHFFFAOYSA-N n-[2-(3-benzoyl-7-methoxynaphthalen-1-yl)ethyl]cyclopropanecarboxamide Chemical compound C12=CC(OC)=CC=C2C=C(C(=O)C=2C=CC=CC=2)C=C1CCNC(=O)C1CC1 SUHJKACZNPFDHW-UHFFFAOYSA-N 0.000 description 1
- LNWNMXCJVYWMJH-UHFFFAOYSA-N n-[2-(3-benzoyl-7-methoxynaphthalen-1-yl)ethyl]ethanethioamide Chemical compound C1=C(CCNC(C)=S)C2=CC(OC)=CC=C2C=C1C(=O)C1=CC=CC=C1 LNWNMXCJVYWMJH-UHFFFAOYSA-N 0.000 description 1
- KEGGPXKOUKALNY-UHFFFAOYSA-N n-[2-(3-benzoyl-7-methoxynaphthalen-1-yl)ethyl]hexanamide Chemical compound C=1C2=CC=C(OC)C=C2C(CCNC(=O)CCCCC)=CC=1C(=O)C1=CC=CC=C1 KEGGPXKOUKALNY-UHFFFAOYSA-N 0.000 description 1
- UIUYIWNGMZDATD-UHFFFAOYSA-N n-[2-(3-benzoyl-7-methoxynaphthalen-1-yl)ethyl]propanamide Chemical compound C=1C2=CC=C(OC)C=C2C(CCNC(=O)CC)=CC=1C(=O)C1=CC=CC=C1 UIUYIWNGMZDATD-UHFFFAOYSA-N 0.000 description 1
- LCPLSQCVQRFWLL-UHFFFAOYSA-N n-[2-(3-benzoyl-7-pentoxynaphthalen-1-yl)ethyl]acetamide Chemical compound C1=C(CCNC(C)=O)C2=CC(OCCCCC)=CC=C2C=C1C(=O)C1=CC=CC=C1 LCPLSQCVQRFWLL-UHFFFAOYSA-N 0.000 description 1
- NMDDJWQMDXRGOG-UHFFFAOYSA-N n-[2-(3-benzoyl-7-phenylmethoxynaphthalen-1-yl)ethyl]acetamide Chemical compound C1=C2C(CCNC(=O)C)=CC(C(=O)C=3C=CC=CC=3)=CC2=CC=C1OCC1=CC=CC=C1 NMDDJWQMDXRGOG-UHFFFAOYSA-N 0.000 description 1
- MNGWNGPWIUDZCV-UHFFFAOYSA-N n-[2-(3-benzoyl-7-prop-2-ynoxynaphthalen-1-yl)ethyl]acetamide Chemical compound C=1C2=CC=C(OCC#C)C=C2C(CCNC(=O)C)=CC=1C(=O)C1=CC=CC=C1 MNGWNGPWIUDZCV-UHFFFAOYSA-N 0.000 description 1
- SIBCSIHGNHQGPR-UHFFFAOYSA-N n-[2-(3-benzoyl-7-propoxynaphthalen-1-yl)ethyl]acetamide Chemical compound C1=C(CCNC(C)=O)C2=CC(OCCC)=CC=C2C=C1C(=O)C1=CC=CC=C1 SIBCSIHGNHQGPR-UHFFFAOYSA-N 0.000 description 1
- XBXJBTHFVSRCBQ-UHFFFAOYSA-N n-[2-(3-benzoylnaphthalen-1-yl)ethyl]cyclobutanecarboxamide Chemical compound C1CCC1C(=O)NCCC(C1=CC=CC=C1C=1)=CC=1C(=O)C1=CC=CC=C1 XBXJBTHFVSRCBQ-UHFFFAOYSA-N 0.000 description 1
- YNHJVKGGSPEXIV-UHFFFAOYSA-N n-[2-(3-benzoylnaphthalen-1-yl)ethyl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NCCC(C1=CC=CC=C1C=1)=CC=1C(=O)C1=CC=CC=C1 YNHJVKGGSPEXIV-UHFFFAOYSA-N 0.000 description 1
- QIBXYRGIVCZSTG-UHFFFAOYSA-N n-[2-(3-benzyl-7-cyclohexyloxynaphthalen-1-yl)ethyl]acetamide Chemical compound C=1C2=CC=C(OC3CCCCC3)C=C2C(CCNC(=O)C)=CC=1CC1=CC=CC=C1 QIBXYRGIVCZSTG-UHFFFAOYSA-N 0.000 description 1
- PKFQOXSFRLQDCB-UHFFFAOYSA-N n-[2-(3-benzyl-7-ethoxynaphthalen-1-yl)ethyl]acetamide Chemical compound C1=C(CCNC(C)=O)C2=CC(OCC)=CC=C2C=C1CC1=CC=CC=C1 PKFQOXSFRLQDCB-UHFFFAOYSA-N 0.000 description 1
- NLPUGZFAQMFQAA-UHFFFAOYSA-N n-[2-(3-benzyl-7-methoxynaphthalen-1-yl)ethyl]acetamide Chemical compound C1=C(CCNC(C)=O)C2=CC(OC)=CC=C2C=C1CC1=CC=CC=C1 NLPUGZFAQMFQAA-UHFFFAOYSA-N 0.000 description 1
- JZSOCRNYAVCAKO-UHFFFAOYSA-N n-[2-(3-benzyl-7-methoxynaphthalen-1-yl)ethyl]butanamide Chemical compound C=1C2=CC=C(OC)C=C2C(CCNC(=O)CCC)=CC=1CC1=CC=CC=C1 JZSOCRNYAVCAKO-UHFFFAOYSA-N 0.000 description 1
- VBKKOTMZWYRFRR-UHFFFAOYSA-N n-[2-(3-benzyl-7-methoxynaphthalen-1-yl)ethyl]cyclobutanecarboxamide Chemical compound C1=C(CCNC(=O)C2CCC2)C2=CC(OC)=CC=C2C=C1CC1=CC=CC=C1 VBKKOTMZWYRFRR-UHFFFAOYSA-N 0.000 description 1
- VTEQAIBHLQFZSU-UHFFFAOYSA-N n-[2-(3-benzyl-7-methoxynaphthalen-1-yl)ethyl]cyclohexanecarboxamide Chemical compound C1=C(CCNC(=O)C2CCCCC2)C2=CC(OC)=CC=C2C=C1CC1=CC=CC=C1 VTEQAIBHLQFZSU-UHFFFAOYSA-N 0.000 description 1
- JCJOVHWPIYACNF-UHFFFAOYSA-N n-[2-(3-benzyl-7-methoxynaphthalen-1-yl)ethyl]cyclopentanecarboxamide Chemical compound C1=C(CCNC(=O)C2CCCC2)C2=CC(OC)=CC=C2C=C1CC1=CC=CC=C1 JCJOVHWPIYACNF-UHFFFAOYSA-N 0.000 description 1
- GRXWFVPXWDOJDI-UHFFFAOYSA-N n-[2-(3-benzyl-7-methoxynaphthalen-1-yl)ethyl]cyclopropanecarboxamide Chemical compound C1=C(CCNC(=O)C2CC2)C2=CC(OC)=CC=C2C=C1CC1=CC=CC=C1 GRXWFVPXWDOJDI-UHFFFAOYSA-N 0.000 description 1
- OOHVKQIWDYQKSK-UHFFFAOYSA-N n-[2-(3-benzyl-7-methoxynaphthalen-1-yl)ethyl]hexanamide Chemical compound C=1C2=CC=C(OC)C=C2C(CCNC(=O)CCCCC)=CC=1CC1=CC=CC=C1 OOHVKQIWDYQKSK-UHFFFAOYSA-N 0.000 description 1
- BZXDIUMAQFYOAD-UHFFFAOYSA-N n-[2-(3-benzyl-7-methoxynaphthalen-1-yl)ethyl]pentanamide Chemical compound C=1C2=CC=C(OC)C=C2C(CCNC(=O)CCCC)=CC=1CC1=CC=CC=C1 BZXDIUMAQFYOAD-UHFFFAOYSA-N 0.000 description 1
- FGGBSOQGSUPIIM-UHFFFAOYSA-N n-[2-(3-benzyl-7-methoxynaphthalen-1-yl)ethyl]propanamide Chemical compound C=1C2=CC=C(OC)C=C2C(CCNC(=O)CC)=CC=1CC1=CC=CC=C1 FGGBSOQGSUPIIM-UHFFFAOYSA-N 0.000 description 1
- GNRLTBCONMFLGY-UHFFFAOYSA-N n-[2-(3-benzyl-7-pentoxynaphthalen-1-yl)ethyl]acetamide Chemical compound C1=C(CCNC(C)=O)C2=CC(OCCCCC)=CC=C2C=C1CC1=CC=CC=C1 GNRLTBCONMFLGY-UHFFFAOYSA-N 0.000 description 1
- FOCZVCPTXYXDBU-UHFFFAOYSA-N n-[2-(3-benzyl-7-phenylmethoxynaphthalen-1-yl)ethyl]acetamide Chemical compound C=1C2=CC=C(OCC=3C=CC=CC=3)C=C2C(CCNC(=O)C)=CC=1CC1=CC=CC=C1 FOCZVCPTXYXDBU-UHFFFAOYSA-N 0.000 description 1
- NONCBMSFASVLBG-UHFFFAOYSA-N n-[2-(3-benzyl-7-prop-2-ynoxynaphthalen-1-yl)ethyl]acetamide Chemical compound C=1C2=CC=C(OCC#C)C=C2C(CCNC(=O)C)=CC=1CC1=CC=CC=C1 NONCBMSFASVLBG-UHFFFAOYSA-N 0.000 description 1
- RTLBPJIXFPLDSX-UHFFFAOYSA-N n-[2-(3-benzyl-7-propoxynaphthalen-1-yl)ethyl]acetamide Chemical compound C1=C(CCNC(C)=O)C2=CC(OCCC)=CC=C2C=C1CC1=CC=CC=C1 RTLBPJIXFPLDSX-UHFFFAOYSA-N 0.000 description 1
- AVTODCHBLAYKPS-UHFFFAOYSA-N n-[2-(3-benzylnaphthalen-1-yl)ethyl]acetamide Chemical compound C=1C2=CC=CC=C2C(CCNC(=O)C)=CC=1CC1=CC=CC=C1 AVTODCHBLAYKPS-UHFFFAOYSA-N 0.000 description 1
- NVIYETONKDRAKN-UHFFFAOYSA-N n-[2-(3-benzylnaphthalen-1-yl)ethyl]cyclobutanecarboxamide Chemical compound C1CCC1C(=O)NCCC(C1=CC=CC=C1C=1)=CC=1CC1=CC=CC=C1 NVIYETONKDRAKN-UHFFFAOYSA-N 0.000 description 1
- UDAZQEOCUMGWSZ-UHFFFAOYSA-N n-[2-(3-benzylnaphthalen-1-yl)ethyl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NCCC(C1=CC=CC=C1C=1)=CC=1CC1=CC=CC=C1 UDAZQEOCUMGWSZ-UHFFFAOYSA-N 0.000 description 1
- RNARQVVGGGONGN-UHFFFAOYSA-N n-[2-(3-ethyl-7-methoxynaphthalen-1-yl)ethyl]butanamide Chemical compound C1=C(OC)C=C2C(CCNC(=O)CCC)=CC(CC)=CC2=C1 RNARQVVGGGONGN-UHFFFAOYSA-N 0.000 description 1
- QBEUQEHUTBNJAG-UHFFFAOYSA-N n-[2-(3-ethyl-7-methoxynaphthalen-1-yl)ethyl]cyclobutanecarboxamide Chemical compound C=12C=C(OC)C=CC2=CC(CC)=CC=1CCNC(=O)C1CCC1 QBEUQEHUTBNJAG-UHFFFAOYSA-N 0.000 description 1
- UWGIUKNWBCLNCO-UHFFFAOYSA-N n-[2-(3-ethyl-7-methoxynaphthalen-1-yl)ethyl]cyclohexanecarboxamide Chemical compound C=12C=C(OC)C=CC2=CC(CC)=CC=1CCNC(=O)C1CCCCC1 UWGIUKNWBCLNCO-UHFFFAOYSA-N 0.000 description 1
- WUDWLVWOJUAJGK-UHFFFAOYSA-N n-[2-(3-ethyl-7-methoxynaphthalen-1-yl)ethyl]cyclopentanecarboxamide Chemical compound C=12C=C(OC)C=CC2=CC(CC)=CC=1CCNC(=O)C1CCCC1 WUDWLVWOJUAJGK-UHFFFAOYSA-N 0.000 description 1
- VTPRRTVFLSVTNU-UHFFFAOYSA-N n-[2-(3-ethyl-7-methoxynaphthalen-1-yl)ethyl]cyclopropanecarbothioamide Chemical compound C=12C=C(OC)C=CC2=CC(CC)=CC=1CCNC(=S)C1CC1 VTPRRTVFLSVTNU-UHFFFAOYSA-N 0.000 description 1
- HQZVQVXMCWPMER-UHFFFAOYSA-N n-[2-(3-ethyl-7-methoxynaphthalen-1-yl)ethyl]cyclopropanecarboxamide Chemical compound C=12C=C(OC)C=CC2=CC(CC)=CC=1CCNC(=O)C1CC1 HQZVQVXMCWPMER-UHFFFAOYSA-N 0.000 description 1
- GWRUDQHLRGITCV-UHFFFAOYSA-N n-[2-(3-ethyl-7-methoxynaphthalen-1-yl)ethyl]ethanethioamide Chemical compound C1=C(OC)C=CC2=CC(CC)=CC(CCNC(C)=S)=C21 GWRUDQHLRGITCV-UHFFFAOYSA-N 0.000 description 1
- HZEDYYBBPKFLIV-UHFFFAOYSA-N n-[2-(3-ethyl-7-methoxynaphthalen-1-yl)ethyl]hexanamide Chemical compound C1=C(OC)C=C2C(CCNC(=O)CCCCC)=CC(CC)=CC2=C1 HZEDYYBBPKFLIV-UHFFFAOYSA-N 0.000 description 1
- RCULYIFIOTXPSI-UHFFFAOYSA-N n-[2-(3-ethyl-7-methoxynaphthalen-1-yl)ethyl]pentanamide Chemical compound C1=C(OC)C=C2C(CCNC(=O)CCCC)=CC(CC)=CC2=C1 RCULYIFIOTXPSI-UHFFFAOYSA-N 0.000 description 1
- PDPUCXHBRWBWHS-UHFFFAOYSA-N n-[2-(3-ethyl-7-methoxynaphthalen-1-yl)ethyl]propanamide Chemical compound C1=C(OC)C=C2C(CCNC(=O)CC)=CC(CC)=CC2=C1 PDPUCXHBRWBWHS-UHFFFAOYSA-N 0.000 description 1
- GOERCFJHCHQCEU-UHFFFAOYSA-N n-[2-(3-ethyl-7-pentoxynaphthalen-1-yl)ethyl]acetamide Chemical compound C1=C(CC)C=C(CCNC(C)=O)C2=CC(OCCCCC)=CC=C21 GOERCFJHCHQCEU-UHFFFAOYSA-N 0.000 description 1
- KUGRINNANZRKQC-UHFFFAOYSA-N n-[2-(3-ethyl-7-phenylmethoxynaphthalen-1-yl)ethyl]acetamide Chemical compound C1=CC2=CC(CC)=CC(CCNC(C)=O)=C2C=C1OCC1=CC=CC=C1 KUGRINNANZRKQC-UHFFFAOYSA-N 0.000 description 1
- CWHXCFAGASWWDS-UHFFFAOYSA-N n-[2-(3-ethyl-7-prop-2-ynoxynaphthalen-1-yl)ethyl]acetamide Chemical compound C1=C(OCC#C)C=CC2=CC(CC)=CC(CCNC(C)=O)=C21 CWHXCFAGASWWDS-UHFFFAOYSA-N 0.000 description 1
- ZOPQPJRSYIWSQE-UHFFFAOYSA-N n-[2-(3-ethylnaphthalen-1-yl)ethyl]cyclobutanecarboxamide Chemical compound C=12C=CC=CC2=CC(CC)=CC=1CCNC(=O)C1CCC1 ZOPQPJRSYIWSQE-UHFFFAOYSA-N 0.000 description 1
- BGGYYIIOJZIGLP-UHFFFAOYSA-N n-[2-(3-ethylnaphthalen-1-yl)ethyl]cyclopropanecarboxamide Chemical compound C=12C=CC=CC2=CC(CC)=CC=1CCNC(=O)C1CC1 BGGYYIIOJZIGLP-UHFFFAOYSA-N 0.000 description 1
- VUBBOOVHTBZRTJ-UHFFFAOYSA-N n-[2-(3-hydroxy-7-methoxynaphthalen-1-yl)ethyl]acetamide Chemical compound C1=C(O)C=C(CCNC(C)=O)C2=CC(OC)=CC=C21 VUBBOOVHTBZRTJ-UHFFFAOYSA-N 0.000 description 1
- MAUZONKXUSTVFL-UHFFFAOYSA-N n-[2-(3-hydroxy-7-methoxynaphthalen-1-yl)ethyl]cyclobutanecarboxamide Chemical compound C12=CC(OC)=CC=C2C=C(O)C=C1CCNC(=O)C1CCC1 MAUZONKXUSTVFL-UHFFFAOYSA-N 0.000 description 1
- HWDNPVUQLXTOMX-UHFFFAOYSA-N n-[2-(3-hydroxy-7-methoxynaphthalen-1-yl)ethyl]cyclopropanecarboxamide Chemical compound C12=CC(OC)=CC=C2C=C(O)C=C1CCNC(=O)C1CC1 HWDNPVUQLXTOMX-UHFFFAOYSA-N 0.000 description 1
- BTRCGEBRHAQOLG-UHFFFAOYSA-N n-[2-(3-hydroxy-7-methoxynaphthalen-1-yl)ethyl]propanamide Chemical compound C1=C(OC)C=C2C(CCNC(=O)CC)=CC(O)=CC2=C1 BTRCGEBRHAQOLG-UHFFFAOYSA-N 0.000 description 1
- XAVGJASJOXINSZ-UHFFFAOYSA-N n-[2-(3-propanoylnaphthalen-1-yl)ethyl]acetamide Chemical compound C1=CC=CC2=CC(C(=O)CC)=CC(CCNC(C)=O)=C21 XAVGJASJOXINSZ-UHFFFAOYSA-N 0.000 description 1
- PCMVKNOCOWICOO-UHFFFAOYSA-N n-[2-(3-propanoylnaphthalen-1-yl)ethyl]cyclobutanecarboxamide Chemical compound C=12C=CC=CC2=CC(C(=O)CC)=CC=1CCNC(=O)C1CCC1 PCMVKNOCOWICOO-UHFFFAOYSA-N 0.000 description 1
- PUTOQBXTPZFSCL-UHFFFAOYSA-N n-[2-(3-propanoylnaphthalen-1-yl)ethyl]cyclopropanecarboxamide Chemical compound C=12C=CC=CC2=CC(C(=O)CC)=CC=1CCNC(=O)C1CC1 PUTOQBXTPZFSCL-UHFFFAOYSA-N 0.000 description 1
- KMBXOLPHAUVLHW-UHFFFAOYSA-N n-[2-(7-cyclohexyloxy-3-ethylnaphthalen-1-yl)ethyl]acetamide Chemical compound C1=CC2=CC(CC)=CC(CCNC(C)=O)=C2C=C1OC1CCCCC1 KMBXOLPHAUVLHW-UHFFFAOYSA-N 0.000 description 1
- GTYPINSIAIDYIZ-UHFFFAOYSA-N n-[2-(7-ethoxy-3-ethylnaphthalen-1-yl)ethyl]acetamide Chemical compound C1=C(CC)C=C(CCNC(C)=O)C2=CC(OCC)=CC=C21 GTYPINSIAIDYIZ-UHFFFAOYSA-N 0.000 description 1
- KXROLJCJBYLYBD-UHFFFAOYSA-N n-[2-(7-methoxy-3-propanoylnaphthalen-1-yl)ethyl]butanamide Chemical compound C1=C(OC)C=C2C(CCNC(=O)CCC)=CC(C(=O)CC)=CC2=C1 KXROLJCJBYLYBD-UHFFFAOYSA-N 0.000 description 1
- SPWJWPKSNIDXAL-UHFFFAOYSA-N n-[2-(7-methoxy-3-propanoylnaphthalen-1-yl)ethyl]cyclobutanecarboxamide Chemical compound C=12C=C(OC)C=CC2=CC(C(=O)CC)=CC=1CCNC(=O)C1CCC1 SPWJWPKSNIDXAL-UHFFFAOYSA-N 0.000 description 1
- LUDIRXSHTXESGV-UHFFFAOYSA-N n-[2-(7-methoxy-3-propanoylnaphthalen-1-yl)ethyl]cyclopropanecarboxamide Chemical compound C=12C=C(OC)C=CC2=CC(C(=O)CC)=CC=1CCNC(=O)C1CC1 LUDIRXSHTXESGV-UHFFFAOYSA-N 0.000 description 1
- PQHHHADQHYBVJB-UHFFFAOYSA-N n-[2-(7-methoxy-3-propanoylnaphthalen-1-yl)ethyl]propanamide Chemical compound C1=C(OC)C=C2C(CCNC(=O)CC)=CC(C(=O)CC)=CC2=C1 PQHHHADQHYBVJB-UHFFFAOYSA-N 0.000 description 1
- PCPNZTFUPSDJNK-UHFFFAOYSA-N n-[2-(7-methoxy-3-propylnaphthalen-1-yl)ethyl]acetamide Chemical compound C1=C(OC)C=CC2=CC(CCC)=CC(CCNC(C)=O)=C21 PCPNZTFUPSDJNK-UHFFFAOYSA-N 0.000 description 1
- TZQAGPUEZZMDSL-UHFFFAOYSA-N n-[2-(7-methoxynaphthalen-1-yl)ethyl]cyclopropanecarboxamide Chemical compound C12=CC(OC)=CC=C2C=CC=C1CCNC(=O)C1CC1 TZQAGPUEZZMDSL-UHFFFAOYSA-N 0.000 description 1
- NUCRUAALXFPTSQ-UHFFFAOYSA-N n-[2-(furan-2-ylmethyl)cyclohexyl]naphthalene-1-carboxamide Chemical compound C=1C=CC2=CC=CC=C2C=1C(=O)NC1CCCCC1CC1=CC=CO1 NUCRUAALXFPTSQ-UHFFFAOYSA-N 0.000 description 1
- FJJWWPDBUIDKCU-UHFFFAOYSA-N n-[2-[3-(cyclopropanecarbonyl)-7-methoxynaphthalen-1-yl]ethyl]butanamide Chemical compound C=1C2=CC=C(OC)C=C2C(CCNC(=O)CCC)=CC=1C(=O)C1CC1 FJJWWPDBUIDKCU-UHFFFAOYSA-N 0.000 description 1
- MHFAKJBWFSGZPC-UHFFFAOYSA-N n-[2-[3-(cyclopropanecarbonyl)-7-methoxynaphthalen-1-yl]ethyl]cyclobutanecarboxamide Chemical compound C12=CC(OC)=CC=C2C=C(C(=O)C2CC2)C=C1CCNC(=O)C1CCC1 MHFAKJBWFSGZPC-UHFFFAOYSA-N 0.000 description 1
- RESBCRAGCRMLMI-UHFFFAOYSA-N n-[2-[3-(cyclopropanecarbonyl)-7-methoxynaphthalen-1-yl]ethyl]cyclopropanecarboxamide Chemical compound C12=CC(OC)=CC=C2C=C(C(=O)C2CC2)C=C1CCNC(=O)C1CC1 RESBCRAGCRMLMI-UHFFFAOYSA-N 0.000 description 1
- QGURFJGLUDZZOR-UHFFFAOYSA-N n-[2-[3-(cyclopropanecarbonyl)-7-methoxynaphthalen-1-yl]ethyl]propanamide Chemical compound C=1C2=CC=C(OC)C=C2C(CCNC(=O)CC)=CC=1C(=O)C1CC1 QGURFJGLUDZZOR-UHFFFAOYSA-N 0.000 description 1
- LJRRPRGCOQDIOH-UHFFFAOYSA-N n-[2-[3-(cyclopropanecarbonyl)naphthalen-1-yl]ethyl]acetamide Chemical compound C=1C2=CC=CC=C2C(CCNC(=O)C)=CC=1C(=O)C1CC1 LJRRPRGCOQDIOH-UHFFFAOYSA-N 0.000 description 1
- FELBOTVHMPFLSD-UHFFFAOYSA-N n-[2-[3-(cyclopropanecarbonyl)naphthalen-1-yl]ethyl]cyclobutanecarboxamide Chemical compound C1CCC1C(=O)NCCC(C1=CC=CC=C1C=1)=CC=1C(=O)C1CC1 FELBOTVHMPFLSD-UHFFFAOYSA-N 0.000 description 1
- OKXBCUZEVZSHBE-UHFFFAOYSA-N n-[2-[3-(cyclopropanecarbonyl)naphthalen-1-yl]ethyl]cyclopropanecarboxamide Chemical compound C1CC1C(=O)NCCC(C1=CC=CC=C1C=1)=CC=1C(=O)C1CC1 OKXBCUZEVZSHBE-UHFFFAOYSA-N 0.000 description 1
- DNKJZNULHOPSPQ-UHFFFAOYSA-N n-[2-[3-(cyclopropylmethyl)-7-methoxynaphthalen-1-yl]ethyl]acetamide Chemical compound C1=C(CCNC(C)=O)C2=CC(OC)=CC=C2C=C1CC1CC1 DNKJZNULHOPSPQ-UHFFFAOYSA-N 0.000 description 1
- QQVNSZIYAWDZBT-UHFFFAOYSA-N n-[2-[3-acetyl-7-(cyclohexen-1-yloxy)naphthalen-1-yl]ethyl]acetamide Chemical compound C1=C2C(CCNC(=O)C)=CC(C(C)=O)=CC2=CC=C1OC1=CCCCC1 QQVNSZIYAWDZBT-UHFFFAOYSA-N 0.000 description 1
- MIUSGSDLBCLIQA-UHFFFAOYSA-N n-[2-[3-acetyl-7-(cyclopropylmethoxy)naphthalen-1-yl]ethyl]acetamide Chemical compound C1=C2C(CCNC(=O)C)=CC(C(C)=O)=CC2=CC=C1OCC1CC1 MIUSGSDLBCLIQA-UHFFFAOYSA-N 0.000 description 1
- SHANBJFLWUJSDR-UHFFFAOYSA-N n-[2-[3-benzoyl-7-(cyclohexen-1-yloxy)naphthalen-1-yl]ethyl]acetamide Chemical compound C1=C2C(CCNC(=O)C)=CC(C(=O)C=3C=CC=CC=3)=CC2=CC=C1OC1=CCCCC1 SHANBJFLWUJSDR-UHFFFAOYSA-N 0.000 description 1
- SFKKIQDPCARULD-UHFFFAOYSA-N n-[2-[3-benzoyl-7-(cyclopropylmethoxy)naphthalen-1-yl]ethyl]acetamide Chemical compound C1=C2C(CCNC(=O)C)=CC(C(=O)C=3C=CC=CC=3)=CC2=CC=C1OCC1CC1 SFKKIQDPCARULD-UHFFFAOYSA-N 0.000 description 1
- DVQKGPXNCVLNDP-UHFFFAOYSA-N n-[2-[3-benzyl-7-(cyclohexen-1-yloxy)naphthalen-1-yl]ethyl]acetamide Chemical compound C=1C2=CC=C(OC=3CCCCC=3)C=C2C(CCNC(=O)C)=CC=1CC1=CC=CC=C1 DVQKGPXNCVLNDP-UHFFFAOYSA-N 0.000 description 1
- MHWHKVJURRODRC-UHFFFAOYSA-N n-[2-[3-benzyl-7-(cyclopropylmethoxy)naphthalen-1-yl]ethyl]acetamide Chemical compound C=1C2=CC=C(OCC3CC3)C=C2C(CCNC(=O)C)=CC=1CC1=CC=CC=C1 MHWHKVJURRODRC-UHFFFAOYSA-N 0.000 description 1
- KKJJMBUWNZRIAL-UHFFFAOYSA-N n-[2-[7-(cyclohexen-1-yloxy)-3-ethylnaphthalen-1-yl]ethyl]acetamide Chemical compound C1=CC2=CC(CC)=CC(CCNC(C)=O)=C2C=C1OC1=CCCCC1 KKJJMBUWNZRIAL-UHFFFAOYSA-N 0.000 description 1
- QTHYCKRBMJTKMV-UHFFFAOYSA-N n-[2-[7-(cyclopropylmethoxy)-3-ethylnaphthalen-1-yl]ethyl]acetamide Chemical compound C1=CC2=CC(CC)=CC(CCNC(C)=O)=C2C=C1OCC1CC1 QTHYCKRBMJTKMV-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000027317 positive regulation of immune response Effects 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/30—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
- C07C233/31—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/60—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/61—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by doubly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
- C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/26—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/38—Amides of thiocarboxylic acids
- C07C327/40—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C327/42—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/38—Amides of thiocarboxylic acids
- C07C327/46—Amides of thiocarboxylic acids having carbon atoms of thiocarboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (10)
1. Verbindungen der allgemeinen Formel (1):
in der:
. R ein Wasserstoffatom oder eine Gruppe ausgewählt aus Alkyl,
substituiertem Alkyl und Gruppen -O-R', worin R' ein Wasserstoffatom oder eine
Alkylgruppe, substituierte Alkylgruppe, Cycloalkylgruppe, substituierte
Cycloalkylgruppe, Cycloalkylalkylgruppe, substituierte Cycloalkylalkylgruppe,
Phenylgruppe, substituierte Phenylgruppe, Phenylalkylgruppe,
substituierte Phenylalkylgruppe, Diphenylalkylgruppe oder substituierte
Diphenylalkylgruppe darstellt:
R&sub1; ein Wasserstoffatom oder eine Alkylgruppe:
R&sub2;a) - -R&sub4;&sub0;
in der X¹ ein Schwefelatom oder ein Sauerstoffatom und R&sub4;&sub0; ein Wasserstoffatom
oder eine Gruppe ausgewählt aus Alkyl, substituiertem Alkyl, Cycloalkyl,
substituiertem Cycloalkyl, Cycloalkylalkyl, substituiertem Cycloalkylalkyl, Alkenyl,
substituiertem Alkenyl, Alkinyl und substituiertem Alkinyl darstellen;
oder b) - - NH - R&sub4;&sub1;
in der X² ein Schwefelatom oder ein Sauerstoffatom und R&sub4;&sub1; ein Wasserstoffatom
oder eine Gruppe ausgewählt aus Alkyl, Cycloalkyl und Cycloalkylalkyl
darstellen:
R&sub3; eine Gruppe ausgewählt aus:
- (C&sub2;-C&sub6;)-Alkyl,
- substituiertem (C&sub2;-C&sub6;)-Alkyl,
- Cycloalkylalkyl,
- substituiertem Cycloalkylalkyl,
- Alkenyl.
- substituiertem Alkenyl,
- Alkinyl,
- substituiertem Alkinyl,
- Hydroxyl in der 3-Stellung,
- R&sub5;-Alkyl-, worin R&sub5; substituiert oder nicht substituiert ist und eine
Gruppe ausgewählt aus Pyridyl, Phenyl, Naphthyl, Thienyl, Furyl,
Pyrimidyl, Indolyl, Benzofuryl, Benzothienyl, Chinolyl und Isochinolyl
darstellt;
- R&sub6;-CO-O- und
R&sup6;-CO-,
worin R&sub6; eine Gruppe ausgewählt aus (C&sub1;-C&sub5;)-Alkyl. substituiertem (C&sub1;-
C&sub5;)-Alkyl, Cycloalkyl, substituiertem Cycloalkyl,
Cycloalkyl-(C&sub1;-C&sub5;)-alkyl, substituiertem Cycloalkyl-(C&sub1;-C&sub5;) -alkyl, R&sub5;- und R&sub5;-Alkyl-, worin
R&sub5;, welches substituiert oder nicht substituiert ist, die oben angegebenen
Bedeutungen besitzt, darstellt,
bedeuten, mit der Maßgabe, daß
die Verbindung der allgemeinen Formel (I) nicht
N-(2-[(4-Acetyl)-naphth-1-yl]-ethyl}-acetamid ist,
- die Begriffe "Alkyl" und "Alkoxy", wenn nichts anderes angegeben ist,
geradkettige oder verzweigte Gruppen mit 1 bis 6 Kohlenstoffatomen
darstellen,
- die Begriffe "Alkenyl" und "Alkinyl" für ungesättigte, geradkettige oder
verzweigte Gruppen mit 2 bis 6 Kohlenstoffatomen stehen,
- der Begriff "Cycloalkyl" für eine cyclische Gruppe mit 3 bis 8
Kohlenstoffatomen steht,
- der Begriff "substituiert" unter Bezugnahme auf "Alkyl", "Alkoxy",
"Alkenyl", "Alkinyl", "Cycloalkyl" oder "Cycloalkylalkyl" bedeutet, daß diese
Gruppen durch eine oder mehrere Gruppen ausgewählt aus Alkyl,
Alkoxy- und Halogen substituiert sind;
- der Begriff "substituiert" unter Bezugnahme auf R&sub5; und "Phenyl",
"Phenylalkyl" oder "Diphenylalkyl" bedeutet, daß diese Gruppen durch eine
oder mehrere Gruppen ausgewählt aus Alkyl, Alkoxy. Halogen. Hydroxy
und Trifluormethyl substituiert sind;
- deren Enantiomere und Diastereolsomere und
- deren Additionssalze mit einer pharmazeutisch annehmbaren Säure oder
Base.
2. Verbindung nach Anspruch 1, nämlich
N-[2-(7-Methoxy-3-benzoylnaphth-1-yl)-ethyl]-acetamid.
3. Verbindung nach Anspruch 1, nämlich N-[2-(7-Methoxy-3-acetyl-naphth-
1-yl)-ethyl]-acetamid.
4. Verbindung nach Anspruch 1, nämlich N-[2-(7-Methoxy-3-acetyl-naphth-
1-yl)-ethyl]-cyclopropylcarboxamid.
5. Verbindung nach Anspruch 1, nämlich N-[2-(7-Methoxy-3-ethyl-naphth-
1-yl)-ethyl]-acetamid.
6. Verbindung nach Anspruch 1, nämlich
N-[2-(7-Methoxy-3-propyl-naphth-1-yl)-ethyll-acetamid.
7. Verfahren zur Herstellung der Verbindungen der Formel (1) nach Anspruch
1, gemäß dem man eine Verbindung der Formel (II):
in der R, R&sub1; und R&sub2; die in Anspruch 1 angegebenen Bedeutungen besitzen, mit
einer Verbindung der Formel (III):
R&sub6; - COCL (III)
in der R&sub6; die in Anspruch 1 angegebenen Bedeutungen besitzt, umsetzt
zur Bildung einer entsprechenden Verbindung der Formel (Ia):
in der R, R&sub1;, R&sub2; und R&sub6; die oben angegebenen Bedeutungen besitzen,
welche man gewünschtenfalls
- entweder einer Oxidation nach einer Baeyer-Villiger-Reaktion unterwirft
zur Bildung einer entsprechenden Verbindung der Formel (Ib):
in der R, R&sub1;, R&sub2; und R&sub6; die oben angegebenen Bedeutungen besitzen, wonach
man, wenn der Substituent -O-CO-R&sub6; in der 3-Stellung steht, die Verbindung
einer Verseifung in Gegenwart von Natriumhydroxid unterwirft zur Bildung der
entsprechenden Verbindung der Formel (Ic):
in der R, R&sub1; und R&sub2; die oben angegebenen Bedeutungen besitzen,
- oder einer Reduktion mit Quecksilber und Zink in Gegenwart von Toluol und
Chlorwasserstoffsäure unterwirft zur Bildung einer entsprechenden
Verbindung der Formel (Id):
in der R, R&sub1;, R&sub2; und R&sub6; die oben angegebenen Bedeutungen besitzen,
welche Verbindungen der Formeln (Ia), (Ib). (Ic) und (Id) gemeinsam die
Verbindungen der Formel (1) bilden,
welche Verbindungen der Formel (I)
- mit Hilfe eines oder mehrerer Reinigungsverfahren ausgewählt aus
Kristallisation, Chromatographie über Kieselgel. Extraktion, Filtration und
Überführung über Aktivkohle oder ein Harz gereinigt werden können,
- gegebenenfalls in die entsprechenden Enantiomeren oder
Diastereolsomeren in reiner Form oder in Form einer Mischung aufgetrennt werden können
- oder mit Hilfe einer pharmazeutisch annehmbaren Säure oder Base in die
Salze überführt werden können.
8. Pharmazeutische Zubereitungen enthaltend die Produkte der Formel (I)
nach Anspruch 1 oder gegebenenfalls eines ihrer Additionssalze mit einer
pharmazeutisch annehmbaren Säure oder Base in Kombination mit einem oder
mehreren pharmazeutisch annehmbaren Trägermaterialien.
9. Pharmazeutische Zubereitungen nach Anspruch 8 zur Behandlung von
melatoninergischen Störungen.
10. Pharmazeutische Zubereitungen nach Anspruch 9 zur Behandlung von
saisonal bestimmten Depressionen, Schlafstörungen, kardiovaskulären
pathologischen Zuständen, der Schlaflosigkeit und der Müdigkeit als Folge von
Zeitverschiebungen und Appetitstörungen und der Fettsucht.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9314630A FR2713636B1 (fr) | 1993-12-07 | 1993-12-07 | Nouveaux dérivés naphtaléniques, leur procédé de préparation, et les compositions pharmaceutiques qui les contiennent. |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69408962D1 DE69408962D1 (de) | 1998-04-16 |
DE69408962T2 true DE69408962T2 (de) | 1998-10-08 |
Family
ID=9453623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69408962T Expired - Fee Related DE69408962T2 (de) | 1993-12-07 | 1994-12-06 | Naphthalen-Derivate mit Affinität für Melatonin-Rezeptoren, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen |
Country Status (13)
Country | Link |
---|---|
US (2) | US5591775A (de) |
EP (1) | EP0662471B1 (de) |
JP (1) | JP2688179B2 (de) |
AT (1) | ATE163919T1 (de) |
AU (1) | AU677868B2 (de) |
CA (1) | CA2137445C (de) |
DE (1) | DE69408962T2 (de) |
DK (1) | DK0662471T3 (de) |
ES (1) | ES2116555T3 (de) |
FR (1) | FR2713636B1 (de) |
GR (1) | GR3026634T3 (de) |
NZ (1) | NZ270082A (de) |
ZA (1) | ZA949752B (de) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5849769A (en) * | 1994-08-24 | 1998-12-15 | Medivir Ab | N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection |
ATE193700T1 (de) * | 1994-09-12 | 2000-06-15 | Takeda Chemical Industries Ltd | Benzozykloalkenverbindungen, deren herstellung und verwendung |
FR2734815B1 (fr) * | 1995-05-31 | 1997-07-04 | Adir | Nouveaux composes arylalkyl (thio) carboxamides, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent |
FR2734814B1 (fr) * | 1995-05-31 | 1997-07-04 | Adir | Nouveaux composes alkoxy-aryles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
DE69633289T2 (de) * | 1995-06-27 | 2006-01-12 | Takeda Pharmaceutical Co. Ltd. | 4-acylamino(halogen)alkyl-chinolin derivate, deren herstellung und deren verwendung als melatonin-agonisten |
PT885210E (pt) | 1996-03-08 | 2002-09-30 | Takeda Chemical Industries Ltd | Compostos triciclicos que possuem afinidade de ligacao para receptores de melatonina sua producao e utilizacao |
US6034239A (en) * | 1996-03-08 | 2000-03-07 | Takeda Chemical Industries, Ltd. | Tricyclic compounds, their production and use |
US6310085B1 (en) * | 1997-10-03 | 2001-10-30 | Clarencew Pty Ltd. | Method for the treatment of neurological or neuropsychiatric disorders |
US5958964A (en) * | 1997-02-18 | 1999-09-28 | South Alabama Medical Science Foundation | Use of melatonin to prevent cytotoxic effects of amyloid beta protein |
FR2771739B1 (fr) * | 1997-11-28 | 2001-04-20 | Adir | Nouveaux composes naphtaleniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR2778662B1 (fr) * | 1998-05-12 | 2000-06-16 | Adir | Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
FR2791344B1 (fr) * | 1999-03-25 | 2002-02-15 | Adir | Nouveaux derives dimeriques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
EP1213290B1 (de) | 1999-08-20 | 2005-04-20 | Takeda Pharmaceutical Company Limited | Dihydrobenzofuranderivate, verfahren zu ihrer herstellung und mittel |
WO2008083204A2 (en) * | 2006-12-28 | 2008-07-10 | Braincells, Inc. | Modulation of neurogenesis by melatoninergic ligands |
WO2008137461A1 (en) * | 2007-05-01 | 2008-11-13 | Concert Pharmaceuticals Inc. | Naphthyl(ethyl) acetamides |
FR2918371B1 (fr) * | 2007-07-02 | 2009-08-28 | Servier Lab | Nouveaux derives naphtaleniques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US8691275B2 (en) | 2011-01-28 | 2014-04-08 | Zx Pharma, Llc | Controlled-release melatonin compositions and related methods |
US9532952B2 (en) | 2011-01-28 | 2017-01-03 | Physician's Seal, LLC | Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients |
FR3014437B1 (fr) * | 2013-12-05 | 2016-12-23 | Servier Lab | Nouveau procede de synthese de l'agomelatine |
CN104230742B (zh) * | 2014-08-14 | 2016-08-24 | 广东东阳光药业有限公司 | 萘衍生物及其在药物上的应用 |
CN104292126B (zh) * | 2014-08-14 | 2016-08-24 | 广东东阳光药业有限公司 | 萘衍生物及其在药物上的应用 |
BR112018072795A2 (pt) | 2016-05-06 | 2019-04-30 | Physician's Seal, LLC | composição de valeriana e métodos relacionados |
TW202214558A (zh) * | 2020-07-28 | 2022-04-16 | 大陸商上海翰森生物醫藥科技有限公司 | 雙環類衍生物調節劑、其製備方法和應用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU616907B2 (en) * | 1987-08-17 | 1991-11-14 | Whitby Research, Inc. | Melatonin analogues |
DE3828566A1 (de) * | 1988-08-23 | 1990-03-15 | Thomae Gmbh Dr K | Neue benzolsulfonamido-verbindungen, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
FR2658818B1 (fr) * | 1990-02-27 | 1993-12-31 | Adir Cie | Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
FR2680507B1 (fr) * | 1991-08-23 | 1993-10-08 | Adir Cie | Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
FR2689124A1 (fr) * | 1992-03-27 | 1993-10-01 | Adir | Nouvelles naphtylalkylamines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
-
1993
- 1993-12-07 FR FR9314630A patent/FR2713636B1/fr not_active Expired - Fee Related
-
1994
- 1994-12-05 AU AU80215/94A patent/AU677868B2/en not_active Ceased
- 1994-12-06 DE DE69408962T patent/DE69408962T2/de not_active Expired - Fee Related
- 1994-12-06 EP EP94402789A patent/EP0662471B1/de not_active Expired - Lifetime
- 1994-12-06 DK DK94402789T patent/DK0662471T3/da active
- 1994-12-06 NZ NZ270082A patent/NZ270082A/en not_active IP Right Cessation
- 1994-12-06 JP JP6301805A patent/JP2688179B2/ja not_active Expired - Fee Related
- 1994-12-06 ES ES94402789T patent/ES2116555T3/es not_active Expired - Lifetime
- 1994-12-06 AT AT94402789T patent/ATE163919T1/de not_active IP Right Cessation
- 1994-12-06 US US08/349,914 patent/US5591775A/en not_active Expired - Lifetime
- 1994-12-06 CA CA002137445A patent/CA2137445C/fr not_active Expired - Fee Related
- 1994-12-07 ZA ZA949752A patent/ZA949752B/xx unknown
-
1995
- 1995-05-23 US US08/447,886 patent/US5552418A/en not_active Expired - Lifetime
-
1998
- 1998-04-14 GR GR980400833T patent/GR3026634T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
DK0662471T3 (da) | 1998-12-21 |
DE69408962D1 (de) | 1998-04-16 |
EP0662471A2 (de) | 1995-07-12 |
JPH07224017A (ja) | 1995-08-22 |
NZ270082A (en) | 1995-07-26 |
CA2137445A1 (fr) | 1995-06-08 |
FR2713636A1 (fr) | 1995-06-16 |
JP2688179B2 (ja) | 1997-12-08 |
FR2713636B1 (fr) | 1996-01-05 |
CA2137445C (fr) | 2000-10-24 |
EP0662471B1 (de) | 1998-03-11 |
US5552418A (en) | 1996-09-03 |
AU677868B2 (en) | 1997-05-08 |
ZA949752B (en) | 1995-08-17 |
AU8021594A (en) | 1995-06-15 |
EP0662471A3 (de) | 1995-08-02 |
US5591775A (en) | 1997-01-07 |
ATE163919T1 (de) | 1998-03-15 |
ES2116555T3 (es) | 1998-07-16 |
GR3026634T3 (en) | 1998-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69408962T2 (de) | Naphthalen-Derivate mit Affinität für Melatonin-Rezeptoren, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen | |
DE69606915T2 (de) | Aryl(alkyl)propylamide, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen, die sie enthalten | |
DE69300532T2 (de) | Naphtylalkylamine, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen. | |
DE69206214T2 (de) | Neue Arylethylaminderivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen. | |
DE69032725T2 (de) | ZNS-wirksame 8-Heterocyclyl-2-aminotetralin Derivate | |
DE69933147T2 (de) | Sustiuierte cyclische verbindungen, verfahren zu ihrer herstellung sowie sie enthaltende pharmazeutische zusammesetzungen | |
DE69219394T2 (de) | Heterozyklische Alkylamide, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen | |
DE69303569T2 (de) | Arylalkyl(thio)amide mit Melatonin-Rezeptor-Selektivität und Prozess zu ihrer Darstellung | |
DE69524186T2 (de) | Tricyclische Amidverbindungen, Verfahren zu deren Herstellung und sie enthaltende pharmazeutische Zusammensetzungen | |
DE69605856T2 (de) | Alkoxyarylverbindungen mit Affinität zu den Melatoninrezeptoren, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen | |
KR20080059296A (ko) | 나트륨 채널 조절제로서의 프롤린아미드 유도체 | |
DE69124868T2 (de) | Ring-substituierte 2-Amino-1,2,3,4-tetra-hydronaphthaline, 3-Aminochromane und 3-Aminothiochromane | |
DE69605452T2 (de) | Alkyl(hetero)cyclische Derivate, Verfahren zu deren Herstellung und sie enthaltende pharmazeutische Zusammensetzungen | |
ES2247668T3 (es) | Nuevos compuestos de naftaleno, su procedimiento de preparacion y composiciones farmaceuticas que los contienen. | |
DE69023274T2 (de) | 8-Substituierte-2-Aminotetraline. | |
DE3347867C2 (de) | ||
EP0177960B1 (de) | Tetrahydronaphtalinderivate, Verfahren und Zwischenprodukte zu deren Herstellung sowie diese enthaltende Arzneimittel | |
DE69120899T2 (de) | Neue N-Benzoylprolin-Derivate, Verfahren zur Herstellung und diese enthaltende Arzneimittel | |
DE69517433T2 (de) | Benzozykloalkenverbindungen, deren herstellung und verwendung | |
DE69603309T2 (de) | Tricyclische Amidverbindungen, Verfahren zu deren Herstellung und sie enthaltende pharmazeutische Zusammensetzungen | |
DE69605975T2 (de) | Arylalkyl(thio)carboxamidverbindungen mit Affinität für Melatoninrezeptoren, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen | |
DE4341402A1 (de) | N-substituierte Azabicycloheptan-Derivate, ihre Herstellung und Verwendung | |
EP0646110B1 (de) | N-substituierte 3-azabicyclo[3.2.0]heptan-derivate als neuroleptika | |
DE69906000T2 (de) | Zyklische Derivate mit einer zykloalkylenischen Kette, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen die diese enthalten | |
DE69026816T2 (de) | Bizyklische amino-substituierte verbindungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8327 | Change in the person/name/address of the patent owner |
Owner name: LES LABORATOIRES SERVIER, NEUILLY SUR SEINE, FR |
|
8339 | Ceased/non-payment of the annual fee |